Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the company is scheduled to exhibit 4 abstracts at the ...

Pramode Mallik Updated : Mar 20, 2025, 12:55 PM IST Muslim cleric Chaudhary Ifraheem Husain on Thursday condemned the alleged molestation of policewoman during the Nagpur violence which unfolded three ...

A wondrous world of Studio Ghibli-inspired shenanigans has just opened up on D&D Beyond, and things are about to get strange for dungeon masters and Dungeons & Dragons players alike thanks to ...

However, with that much future growth priced in, Tempus AI stock could not sustain its newfound valuation amid a tidal wave of market volatility set in motion by the tariff war. By press time, ...

It’s attributed to Dan Rawson, senior vice president Dungeons & Dragons and Hasbro Direct. I want to share an important update regarding Sigil. After several months of alpha testing, we’ve ...

Maximum Entertainment and developer Secret Base will be bringing a free DLC pack to their beloved beat ‘em up Double Dragon Gaiden: Rise of the Dragons this April, that will bring two brand-new ...

On Tuesday, Cathie Wood-led Ark Invest made significant trades involving Tempus AI Inc. TEM, Advanced Micro Devices Inc. AMD, and Meta Platforms Inc. META. The Tempus AI Trade saw Ark ...

The Islamic State has claimed responsibility for the assassination of Mufti Abdul Baqi Noorzai, a senior Jamiat Ulema-e-Islam official, in Quetta, Pakistan. The attack highlights ISKP's growing ...

Tempus AI started off the year with a stellar rally, but then bounced back from its peak in early February. There's no way this stock will remain cheap for long. Tempus AI's financials have ...

Level-one Dungeons and Dragons games are something of a paradox. They represent the start of a character’s journey, and they’re often used to onboard total D&D newbies. It makes sense, then, that ...

Guardant Health Inc.'s genomic data-powered technologies for accelerating drug development infringe Tempus AI Inc.'s “groundbreaking” cancer research patents, according to a federal lawsuit.